Jump to content

KEYLYNK-013 Study


LUNGevityHunter

Recommended Posts

Visit  https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04624204 or call 888-577-8839 for more information

KEYLYNK-013 - Placebo-controlled study of concurrent chemoradiation therapy with Pembrolizumab followed by Pembrolizumab and Olaparib in newly diagnosed, treatment-naïve limited-stage small cell lung cancer (LS-SCLC) (NCT04624204)

You can be in this trial if you have newly diagnosed LS-SCLC and have not yet had treatment.

The drug you get will depend on which group you are placed in.  You have a 1 in 3 chance of being placed in each group.

This trial has 3 groups:

Group 1: Pembro with chemotherapy and radiation followed by pembro and olaparib placebo

Group 2: Pembro with chemotherapy and radiation followed by pembro and olaparib

Group 3: Pembro placebo with chemotherapy and radiation followed by pembro placebo and olaparib placebo

You, your trial doctor, and the trial staff won’t know what drug you are getting. In case of a health emergency, they can find out.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.